Vaccines train the body's defenses to fight infections safely. Learn how vaccines work, how the immune system responds, and ...
A new COP30 report finds that rising temperatures, extreme weather, evolving pathogens and climate-driven migration are ...
Nature-based solutions (NBS) have evolved from peripheral components of conservation practice to a pivotal tenet of climate ...
Almost six years since Covid-19 shocked the world, the risk is that pandemic readiness slips precisely as the conditions for ...
CAGAYAN DE ORO CITY (PIA) — Northern Mindanao has remained malaria-free since 2019, the Department of Health–Center for Health Development (DOH-CHD) Northern Mindanao said, but officials urged the ...
Explore Laveran's groundbreaking discovery of the malaria parasite and its lasting impact on infectious disease research and ...
Lyme disease is caused by the bacterium Borrelia burgdorferi. Borrelia burgdorferi relies on the antioxidant manganese to ...
The camp, organised jointly by ICAR–National Meat Research Institute (NMRI), Hyderabad, and AIIMS Bibinagar under the One ...
Learn about Rift Valley Fever's impact, outbreaks, transmission, and global response strategies to manage this zoonotic ...
Genome Alberta, with partners, is funding other genomic research initiatives in agriculture. One of these has the aim of ...
China's National Disease Control and Prevention Administration warned on Monday of a general uptick in acute respiratory ...
AllAfrica on MSN
Encouraging Results From a First-in-Human Phase 1 Clinical Trial of IAVI's Lassa Vaccine Candidate Published in New England Journal of Medicine
One dose elicits robust and long-lasting immune responses in healthy adults in the U.S. and LiberiaKey takeaways: IAVI's Lassa vaccine candidate rVSVΔG-LASV-GPC has an acceptable safety profile and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results